Talia Golan

1997–2025 年に発表

87
論文数
18,924
被引用数
50
h 指数
85
i10 指数

被引用数

Talia Golan の年別被引用数1979 年: 被引用 1 件1996 年: 被引用 1 件2000 年: 被引用 1 件2001 年: 被引用 1 件2002 年: 被引用 2 件2003 年: 被引用 2 件2004 年: 被引用 3 件2005 年: 被引用 1 件2006 年: 被引用 2 件2007 年: 被引用 2 件2008 年: 被引用 1 件2009 年: 被引用 3 件2010 年: 被引用 1 件2011 年: 被引用 3 件2012 年: 被引用 6 件2013 年: 被引用 5 件2014 年: 被引用 8 件2015 年: 被引用 30 件2016 年: 被引用 32 件2017 年: 被引用 101 件2018 年: 被引用 188 件2019 年: 被引用 589 件2020 年: 被引用 996 件2021 年: 被引用 1,378 件2022 年: 被引用 1,232 件2023 年: 被引用 1,006 件2024 年: 被引用 1,584 件2025 年: 被引用 1,005 件2026 年: 被引用 49 件1980〜1995 年は被引用が無いため表示していません1997〜1999 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,439 件、この内訳の 23.2%中国: 引用元論文 2,178 件、この内訳の 20.7%イタリア: 引用元論文 544 件、この内訳の 5.2%ドイツ: 引用元論文 499 件、この内訳の 4.8%イギリス: 引用元論文 483 件、この内訳の 4.6%フランス: 引用元論文 366 件、この内訳の 3.5%日本: 引用元論文 352 件、この内訳の 3.4%カナダ: 引用元論文 287 件、この内訳の 2.7%スペイン: 引用元論文 286 件、この内訳の 2.7%韓国: 引用元論文 266 件、この内訳の 2.5%オランダ: 引用元論文 219 件、この内訳の 2.1%イスラエル: 引用元論文 210 件、この内訳の 2%
0%23.2%その他 22.6%

分野

  • Medicine55.3%
  • Biochemistry, Genetics and Molecular Biology32.7%
  • Immunology and Microbiology7.1%
  • Engineering1.6%
  • Computer Science0.8%
  • Materials Science0.5%
  • その他2%

トピック

  • Cancer Immunotherapy and Biomarkers8.6%
  • Pancreatic and Hepatic Oncology Research7.4%
  • Gut microbiota and health4.7%
  • Cancer Genomics and Diagnostics4.7%
  • Gastric Cancer Management and Outcomes2.5%
  • Cancer Research and Treatments2.4%
  • その他69.7%

共著者

全論文

検索で開く
  1. The human tumor microbiome is composed of tumor type–specific intracellular bacteria

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Elisa A. Rozeman, Christian U. Blank, Anat Ronai, Ron Shaoul, Amnon Amit, Tatiana Dorfman, Ran Kremer, Zvi R. Cohen, Sagi Harnof, Tali Siegal, Einav Yehuda‐Shnaidman, Einav Nili Gal‐Yam, Hagit Shapira, Nicola Baldini, Morgan G. I. Langille, Alon Ben‐Nun, Bella Kaufman, Aviram Nissan, Talia Golan, Maya Dadiani, Keren Levanon, Jair Bar, Shlomit Yust‐Katz, Iris Barshack, Daniel S. Peeper, Dan J. Raz, Eran Segal, Jennifer A. Wargo, Judith Sandbank, Noam Shental, Ravid Straussman - Science 2020 被引用: 2,471

  2. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey Bu, Monia Michaud, Sunia A. Trauger, Iris Barshack, Talia Golan, Judith Sandbank, Keith T. Flaherty, Anna Mandinova, Wendy S. Garrett, Sarah P. Thayer, Cristina R. Ferrone, Curtis Huttenhower, Sangeeta N. Bhatia, Dirk Gevers, Jennifer A. Wargo, Todd R. Golub, Ravid Straussman - Science 2017 被引用: 1,812

  3. Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2019 被引用: 2,213

  4. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA Oncology 2018 被引用: 1,812

  5. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2023 被引用: 538

  6. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

    著者: , , , , , , , , , , , - Annals of Oncology 2023 被引用: 511

  7. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2020 被引用: 533

  8. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆

    著者: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2021 被引用: 287

  9. Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

    著者: , , , , , , , , , - Annals of Oncology 2018 被引用: 276

  10. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

    著者: , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 1,131

  11. A deep-learning framework to predict cancer treatment response from histopathology images through imputed transcriptomics

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eytan Ruppin - Nature Cancer 2024 被引用: 133

  12. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    著者: , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 225

  13. Identification of tissue-specific cell death using methylation patterns of circulating DNA

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Yuval Dor - National Academy of Sciences, Proceedings of the National Academy of Sciences 2016 被引用: 621

  14. RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients

    著者: , , , , , , , , , , , , , , , , , - Oncotarget 2015 被引用: 326

  15. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers

    著者: , , , , , , , , , , , , , , , , , - Gastroenterology 2019 被引用: 337

  16. A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer

    著者: , , , , , , , , , , , , , , , - ESMO Open 2022 被引用: 88

  17. RBFOX2 modulates a metastatic signature of alternative splicing in pancreatic cancer

    著者: , , , , , , , , , , , , , , , , , , , - Nature 2023 被引用: 90

  18. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 398

  19. Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sarah P. Thayer, Calvin Law, Sulaiman Nanji, Talia Golan, Alyssa Smith, Ayelet Borgida, Anna Dodd, David W. Hedley, Bradly G. Wouters, Grainne M. O’Kane, Julie M. Wilson, George Zogopoulos, Faiyaz Notta, Jennifer J. Knox, Steven Gallinger - Cancer Cell 2019 被引用: 247

  20. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations

    著者: , , , , , , , , , , , , , , - Gastrointestinal Endoscopy 2022 被引用: 134

  21. Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice

    著者: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2024 被引用: 78

  22. BRCA mutational status shapes the stromal microenvironment of pancreatic cancer linking clusterin expression in cancer associated fibroblasts with HSF1 signaling

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2022 被引用: 82

  23. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Gastroenterology 2021 被引用: 152

  24. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

    著者: , , , , , , , , , , , , , - British Journal of Cancer 2014 被引用: 438